Loading...
Guest User
Welcome! Please login.
| IPO Listing At | NSE SME |
| SME IPO Issue Type | Book Build Issue |
| Total Issue Size | ₹52.43 Cr |
| Reserved for Market Maker | ₹2.63 Cr |
| Net Issue Size | ₹52.43 Cr |
| Fresh Issue | ₹44.56 Cr |
| Offer for Sale | ₹5.24 Cr |
| Face Value | ₹10 Per Equity Share |
| Price Band | ₹132.00-139.00 per share |
| NSE Code | BMLL |
| Registrar | Skyline Financial Services Pvt.Ltd. |
| Lead Managers |
Narnolia Financial Services Ltd. |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 2,000 shares · Multiples of 1,000 shares
Bio Medica Laboratories is engaged in the manufacturing of pharmaceutical parenteral formulations, with a focus on liquid and dry powder injectables for both human and veterinary healthcare applications. The company produces a broad range of ethical medicines, generic formulations, and over-the-counter (OTC) pharmaceutical products.
Its injectable products are manufactured in both single-dose and multi-dose formats to cater to diverse therapeutic and clinical requirements.
Product portfolio:
The company offers a diversified pharmaceutical portfolio comprising generic medicines, branded formulations, OTC products, and other injectable medications across multiple therapeutic categories.
Bio Medica Laboratories primarily operates under a B2B contract manufacturing model, developing and manufacturing formulations for pharmaceutical companies based on their specific product requirements and technical specifications.
The company holds certifications for Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP), issued by the Food & Drugs Administration, Madhya Pradesh, reflecting its focus on quality and regulatory compliance.
It operates through two manufacturing facilities located in Indore, Madhya Pradesh.
Competitive strengths:
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Repayment of loan | 6.50 |
| 2 | Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises | 28.50 |
| 3 | General Corporate Purposes | 7.05 |
| 4 | Issue Expense | 5.14 |
| Total | 47.19 |
| Period Ended | 30 Nov 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 65.17 | 39.12 | 19.53 | 17.57 |
| Total Income | 28.63 | 38.33 | 15.34 | 16.25 |
| Profit After Tax | 8.66 | 9.79 | 2.50 | 0.33 |
| EBITDA | 13.45 | 15.21 | 5.63 | 1.70 |
| NET Worth | 17.12 | 14.73 | 4.94 | 2.44 |
| Reserves and Surplus | 7.94 | 5.55 | 4.84 | 2.34 |
| Total Borrowing | 38.17 | 15.01 | 10.49 | 9.61 |
| Amount in ₹ Crore | ||||
| KPI | Nov 30, 2025 | Mar 31, 2025 |
|---|---|---|
| ROE | 54.41% | 99.59% |
| ROCE | 23.22% | 48.20% |
| Debt / Equity | 2.23% | 1.02% |
| RoNW | 54.41% | 99.59% |
| PAT Margin | 30.35% | 25.64% |
| EBITDA Margin | 47.11% | 39.83% |
| Price to Book Value | 8.66 |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 10.67 | 10.33 |
| P/E (x) | 13.03 | 13.45 |
| Promoter Holding | 96.84% | |
| Market Cap | ₹174.79 Cr. | |
